Drugs / TAS0953/HM06
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04683250 | Dec 2020 → Mar 2030 expected | non-small cell lung carcinoma | Taiho Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS0953/HM06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04683250 ↗ |
| Action | Inhibit | “selective RET inhibitor” NCT04683250 ↗ |
| Route | Oral | “Phase 2: oral” NCT04683250 ↗ |
| Target | RET | “selective RET inhibitor” NCT04683250 ↗ |